Virology Research Today is a free monthly online journal that collates and summarizes the latest research about Virology, including details on viruses, pathology, classification, definitions.

Volume 2 (2006), Issue 3 (March)

1. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.
   AIDS, 20(2): 223-31. [Abstract] [Full-text]
2. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.
   AIDS, 20(2): 207-15. [Abstract] [Full-text]
3. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses.
   J Gastroenterol Hepatol, 21(2): 384-91. [Abstract] [Full-text]
4. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
   AIDS, 20(5): 711-8. [Abstract] [Full-text]
5. Phylogenetic, virological, and clinical characteristics of genotype C hepatitis B virus with TCC at codon 15 of the precore region.
   J Clin Microbiol, 44(3): 681-7. [Abstract] [Full-text]
6. Practical experience of high throughput real time PCR in the routine diagnostic virology setting.
   J Clin Virol, 35(4): 355-67. [Abstract] [Full-text]
7. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
   J Clin Virol, 35(4): 414-9. [Abstract] [Full-text]
8. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response.
   Infect Dis Clin North Am, 20(1): 115-35. [Abstract] [Full-text]
9. Molecular virology of the hepatitis C virus: implication for novel therapies.
   Infect Dis Clin North Am, 20(1): 81-98. [Abstract] [Full-text]
10. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
    Gastroenterology, 130(3): 632-8. [Abstract] [Full-text]
11. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
    Arch Intern Med, 166(5): 521-8. [Abstract] [Full-text]
12. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview.
    J Acquir Immune Defic Syndr, 41(3): 323-31. [Abstract] [Full-text]
13. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors.
    J Acquir Immune Defic Syndr, 41(3): 315-22. [Abstract] [Full-text]
14. Declining sustained virological response in hepatitis C.
    J Coll Physicians Surg Pak, 16(3): 187-91. [Abstract] [Full-text]
15. Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.
    AIDS Res Hum Retroviruses, 22(3): 222-31. [Abstract] [Full-text]
16. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.
    AIDS Res Hum Retroviruses, 22(3): 213-21. [Abstract] [Full-text]
17. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
    Aliment Pharmacol Ther, 23(6): 777-85. [Abstract] [Full-text]

© 2005-2008 Virology Research Today. All Rights Reserved.